At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced strategic partnerships with US medical device and life sciences company GE Healthcare Technologies Inc., (NASDAQ: GEHC), and Chinese firms Shanghai Pharmaceuticals Holding Co., Ltd (HKG: 2607, SHA: 601607; SPH) and C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950). These collaborations aim to enhance the construction of a radiology and therapy (RLT) ecosystem, facilitate the introduction and layout of RLT, and make precision cancer treatment more accessible to patients in China.
Joint Initiatives in Precision Medicine and RLT Supply Network
Novartis and GE Healthcare will jointly initiate a precision medicine ecosystem that integrates radioligand therapy (RLT) and radioligand imaging (RLI), promoting the comprehensive application of precision diagnosis and treatment for tumors. Concurrent, the partnerships with SPH and C.Q. Pharma, both key players in the pharmaceutical supply chain, will capitalize on their resource advantages to bolder the supply network layout of radiology and therapy across China.- Flcube.com
